The past year hasn’t been kind to the stocks featured in this article. Each has tumbled to its lowest point in 12 months, leaving investors to decide whether they’re witnessing fire sales or falling knives.
At StockStory, we dig beneath the surface of price movements to uncover whether a company’s fundamentals justify its current valuation or suggest hidden potential. That said, here are two stocks where the poor sentiment is creating a buying opportunity and one where the outlook is warranted.
One Stock to Sell:
Offerpad (OPAD)
One-Month Return: -23.7%
Known for giving homeowners cash offers within 24 hours, Offerpad (NYSE: OPAD) operates a tech-enabled platform specializing in direct home buying and selling solutions.
Why Do We Steer Clear of OPAD?
- Number of homes sold has disappointed over the past two years, indicating weak demand for its offerings
- Diminishing returns on capital from an already low starting point show that neither management’s prior nor current bets are going as planned
- Unprofitable operations could lead to additional rounds of dilutive equity financing if the credit window closes
Offerpad’s stock price of $3.31 implies a valuation ratio of 0x forward price-to-sales. To fully understand why you should be careful with OPAD, check out our full research report (it’s free).
Two Stocks to Watch:
Byrna (BYRN)
One-Month Return: +0%
Providing civilians with tools to disable, disarm, and deter would-be assailants, Byrna (NASDAQ: BYRN) is a provider of non-lethal weapons.
Why Should You Buy BYRN?
- Market share has increased this cycle as its 35.1% annual revenue growth over the last two years was exceptional
- Free cash flow profile has reached break even, indicating the company has achieved financial self-sustainability
- Historical investments are beginning to pay off as its returns on capital are growing
At $3.44 per share, Byrna trades at 0.8x forward price-to-sales. Is now the right time to buy? Find out in our full research report, it’s free.
Boston Scientific (BSX)
One-Month Return: -10.6%
Founded in 1979 with a mission to advance less-invasive medicine, Boston Scientific (NYSE: BSX) develops and manufactures medical devices used in minimally invasive procedures across cardiovascular, urological, neurological, and gastrointestinal specialties.
Why Do We Like BSX?
- Core business can prosper without any help from acquisitions as its organic revenue growth averaged 15.8% over the past two years
- Additional sales over the last five years increased its profitability as the 18.6% annual growth in its earnings per share outpaced its revenue
- Free cash flow margin expanded by 12.3 percentage points over the last five years, providing additional flexibility for investments and share buybacks/dividends
Boston Scientific is trading at $43.24 per share, or 13.4x forward P/E. Is now a good time to buy? See for yourself in our in-depth research report, it’s free.
Stocks We Like Even More
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
